Welcome to CDC Stacks | Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer - 39430 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer
  • Published Date:
    Nov 12 2015
  • Source:
    Biomaterials. 81:46-57.


Public Access Version Available on: March 01, 2017 information icon
Please check back on the date listed above.
Details:
  • Pubmed ID:
    26720500
  • Pubmed Central ID:
    PMC4715938
  • Funding:
    1DP20D006462-01/DP/NCCDPHP CDC HHS/United States
    DP2 OD006462/OD/NIH HHS/United States
    R01CA138533/CA/NCI NIH HHS/United States
    R21 NS085569/NS/NINDS NIH HHS/United States
    R21NS0855691/NS/NINDS NIH HHS/United States
    T32 GM8339/GM/NIGMS NIH HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Stem cell-based gene therapies, wherein stem cells are genetically engineered to express therapeutic molecules, have shown tremendous potential for cancer applications owing to their innate ability to home to tumors. However, traditional stem cell-based gene therapies are hampered by our current inability to control when the therapeutic genes are actually turned on, thereby resulting in detrimental side effects. Here, we report the novel application of magnetic core-shell nanoparticles for the dual purpose of delivering and activating a heat-inducible gene vector that encodes TNF-related apoptosis-inducing ligand (TRAIL) in adipose-derived mesenchymal stem cells (AD-MSCs). By combining the tumor tropism of the AD-MSCs with the spatiotemporal MCNP-based delivery and activation of TRAIL expression, this platform provides an attractive means with which to enhance our control over the activation of stem cell-based gene therapies. In particular, we found that these engineered AD-MSCs retained their innate ability to proliferate, differentiate, and, most importantly, home to tumors, making them ideal cellular carriers. Moreover, exposure of the engineered AD-MSCS to mild magnetic hyperthermia resulted in the selective expression of TRAIL from the engineered AD-MSCs and, as a result, induced significant ovarian cancer cell death in vitro and in vivo.

  • Supporting Files:
    No Additional Files